Physician profile
Amar Bista
NPI 1740266923
$11,997.68
in general payments reported to CMS, 2019-2025
29 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $311 · 2021: $631 · 2022: $6,297 · 2023: $1,371 · 2024: $1,618 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054 · Education: $74.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.48 |
| Education | $74.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $6,652.58 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,215.69 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $804.40 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $508.35 | 2024-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $378.56 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $349.09 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $326.01 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $304.38 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $203.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $149.26 | 2023-2025 | |
| Glaxosmithkline, LLC. | $122.67 | 2021-2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $112.81 | 2020-2021 | |
| Vifor Pharma, INC. | $112.52 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $105.02 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.36 | 2024-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $88.48 | 2023-2024 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $81.37 | 2019-2024 | Injectafer |
| Fresenius USA Marketing, INC. | $73.76 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $62.20 | 2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $44.71 | 2021-2024 | Oxlumo |
| Genzyme Corporation | $34.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.07 | 2024 | Ultomiris |
| Amicus Therapeutics, INC. | $23.05 | 2023 | Galafold |
| Aurinia Pharma U.S., INC. | $22.92 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.60 | 2019 | |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Lilly USA, LLC | $19.31 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $19.05 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Bista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.